Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 4/20 | 0.50 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10886662 | 0.85 | ABCC9 (0.58) | ABCC9 | |
| SCHEMBL16027515 | 0.83 | ABCC9 (0.56) | ABCC9 | |
| SCHEMBL4183551 | 0.81 | ABCB1 (0.50) | ABCB1ABCC9 | |
| SCHEMBL4183553 | 0.81 | ABCB1 (0.50) | ABCB1ABCC9 | |
| SCHEMBL9359250 | 0.80 | ABCC9 (0.52) | ABCB1ABCC9 | |
| SCHEMBL9359246 | 0.80 | ABCC9 (0.52) | ABCB1ABCC9 | |
| SCHEMBL9359239 | 0.80 | ABCC9 (0.52) | ABCB1ABCC9 | |
| SCHEMBL27908188 | 0.80 | ABCC9 (0.53) | ABCC9 | |
| SCHEMBL8343672 | 0.79 | ABCC9 (0.64) | ABCC9 | |
| SCHEMBL3303489 | 0.79 | ABCC9 (0.64) | ABCC9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160115147-A1 | PRO-DRUG COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2016-04-28 | — | — | US | disclosed |
| US-20160115147-A1 | PRO-DRUG COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2016-04-28 | — | — | US | disclosed |
| US-20160016929-A1 | PRO-DRUG COMPOUNDS | PROXIMAGEN LIMITED | 2016-01-21 | — | — | US | disclosed |
| US-20160016929-A1 | PRO-DRUG COMPOUNDS | PROXIMAGEN LIMITED | 2016-01-21 | — | — | US | disclosed |
| US-20140275068-A1 | PRO-DRUG COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
| US-20140275068-A1 | PRO-DRUG COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
| WO-2014140510-A1 | PRO-DRUG COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115147-A1 | PRO-DRUG COMPOUNDS | GJA1, GJB2, AQP3 | ABCB1 617/4885ABCC9 342/4885 |
| US-20160016929-A1 | PRO-DRUG COMPOUNDS | H1-0, ZYX, FURIN | ABCB1 42/4885ABCC9 103/4885 |
| US-20140275068-A1 | PRO-DRUG COMPOUNDS | GJA1, GJB2, AQP3 | ABCB1 617/4885ABCC9 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.